CIMZIA History

A History of Helping Adults Across Six
Chronic Inflammatory Diseases

MORE THAN 110,000 PEOPLE TREATED WITH CIMZIA SINCE 2008

First approved by the FDA in 2008 for adults with moderate to severe Crohn’s disease (not helped enough by usual treatments), CIMZIA was later approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate to severe plaque psoriasis and non-radiographic axial spondyloarthritis.

Today, thousands of doctors choose CIMZIA for their adult patients with chronic inflammatory conditions. Its molecular structure makes CIMZIA the only biologic treatment of its kind.

CIMZIA was most recently FDA-approved in 2019 to treat adults with active non-radiographic axial spondyloarthritis.

Learn what thousands of patients already know. Ask your doctor about The CIMZIA Difference and whether it could be right for you.

Have you been prescribed CIMZIA? Join our mailing list for ongoing support.